Consensus Verastem, Inc.

Stocks

VSTM

US92337C2035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 23:01:14 30/10/2026 +03			5-day change	1st Jan Change
9.920 ^USD	+2.69%		-2.64%	+26.62%

10-15	Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says	MT
10-15	Mizuho Raises Price Target on Verastem to $14 From $13, Keeps Outperform Rating	MT

Evolution of the Average Target: Verastem, Inc.

Evolution of the Target Price: Verastem, Inc.

Changes in Analyst Recommendations: Verastem, Inc.

b4175212c53bb343767e543bf7f7ca73.vySWEtF3UQbESHk_iheisjPglLcBRcnrQCqb8ALoQw4.2G-lXL0VHXS-eCh2yXLr5XWw2dB2IJmJLRqrgjCBBWrZYdQhvwcjY484KA~5f47decfc4644aa745da2538a0f4478e

Analysts' recommendations: Verastem, Inc.

10-15	Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says	MT
10-15	Mizuho Raises Price Target on Verastem to $14 From $13, Keeps Outperform Rating	MT
10-15	RBC Raises Price Target on Verastem to $19 From $14, Keeps Outperform, Speculative Risk	MT
10-07	B. Riley Adjusts Verastem Price Target to $19 From $16, Maintains Buy Rating	MT
09-18	Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says	MT
09-17	Wolfe Research Initiates Verastem at Outperform	MT
08-11	Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating	MT
07-07	RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating	MT
06-24	Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says	MT
05-14	Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
04-29	Mizuho Securities Keeps Verastem Price Target to $16, Maintains Outperform Rating	MT
04-29	Mizuho Securities Adjusts Verastem Price Target to $16 From $18, Maintains Outperform Rating	MT
01-08	RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk	MT
11-05	RBC Capital Adjusts Verastem Price Target to $14 From $13, Maintains Outperform Rating	MT
19/10/25	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma	CI
26/08/25	B. Riley Raises Price Target on Verastem to $16 From $13, Keeps Buy Rating	MT
15/08/25	Mizuho Securities Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
08/08/25	RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk	MT
25/06/25	RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk	MT
09/05/25	B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating	MT
09/05/25	Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating	MT
09/05/25	RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk	MT
28/04/25	B. Riley Adjusts Verastem Price Target to $12 From $9, Maintains Buy Rating	MT
10/04/25	Jefferies Initiates Verastem at Buy With $15 Price Target	MT
08/04/25	Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VERASTEM, INC.					+78.28%
	WUXI APPTEC CO., LTD.					+41.6%
	ARGENX SE					+24.9%
	LONZA GROUP AG					+8.71%
	IQVIA HOLDINGS INC.					+12.62%
	BEONE MEDICINES AG					+17.47%
	REVOLUTION MEDICINES, INC.					+36.04%
	GENMAB A/S					+1%
	CELLTRION, INC.					+42.98%
	WUXI BIOLOGICS (CAYMAN) INC.					+33.85%
	Average					+29.75%
	Weighted average by Cap.					+24.47%